Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 134

1.

Addition of amifostine to the CHOP regimen in elderly patients with aggressive non-Hodgkin lymphoma: a phase II trial showing reduction in toxicity without altering long-term survival.

Gómez HL, Samanéz C, Campana F, Neciosup SP, Vera L, Casanova L, Leon J, Flores C, de Mendoza FH, Casteñeda CA, Pinto JA, Vallejos CS.

Hematol Oncol Stem Cell Ther. 2012;5(3):152-7. doi: 10.5144/1658-3876.2012.152.

PMID:
23095791
[PubMed - indexed for MEDLINE]
2.

Influence of amifostine on toxicity of CHOP in elderly patients with aggressive non-Hodgkin's lymphoma--a phase II study.

Späth-Schwalbe E, Lange C, Genvresse I, Krüger L, Eucker J, Schweigert M, Sezer O, Budach V, Possinger K.

Anticancer Drugs. 2002 Apr;13(4):395-403.

PMID:
11984085
[PubMed - indexed for MEDLINE]
3.

Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505.

Itoh K, Ohtsu T, Fukuda H, Sasaki Y, Ogura M, Morishima Y, Chou T, Aikawa K, Uike N, Mizorogi F, Ohno T, Ikeda S, Sai T, Taniwaki M, Kawano F, Niimi M, Hotta T, Shimoyama M, Tobinai K; Members of the lymphoma study group of the Japan Clinical Oncology Group (JCOG).

Ann Oncol. 2002 Sep;13(9):1347-55.

PMID:
12196359
[PubMed - indexed for MEDLINE]
Free Article
4.

CHOP chemotherapy with preemptive granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma: a dose-intensity analysis.

Jacobson JO, Grossbard M, Shulman LN, Neuberg D.

Clin Lymphoma. 2000 Dec;1(3):211-7; discussion 218.

PMID:
11707832
[PubMed - indexed for MEDLINE]
5.

Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity.

Gómez H, Mas L, Casanova L, Pen DL, Santillana S, Valdivia S, Otero J, Rodriguez W, Carracedo C, Vallejos C.

J Clin Oncol. 1998 Jul;16(7):2352-8.

PMID:
9667250
[PubMed - indexed for MEDLINE]
6.

Long-term results of a multicentre randomised, comparative phase III trial of CHOP versus CNOP regimens in patients with intermediate- and high-grade non-Hodgkin's lymphomas. Novantrone International Study Group.

Bezwoda W, Rastogi RB, Erazo Valla A, Diaz-Maqueo JC, Pavlovsky S, Morioka H, Resegotti L, Rueckle H, Somoza N, Moreno-Nogueira JA, et al.

Eur J Cancer. 1995 Jun;31A(6):903-11.

PMID:
7646919
[PubMed - indexed for MEDLINE]
7.

The effect of optimal treatment on elderly patients with aggressive non-Hodgkin's lymphoma: more patients treated with unaffected response rates.

Peters FP, Fickers MM, Erdkamp FL, Wals J, Wils JA, Schouten HC.

Ann Hematol. 2001 Jul;80(7):406-10.

PMID:
11529466
[PubMed - indexed for MEDLINE]
8.

Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.

Intragumtornchai T, Bunworasate U, Nakorn TN, Rojnuckarin P.

Leuk Lymphoma. 2006 Jul;47(7):1306-14.

PMID:
16923561
[PubMed - indexed for MEDLINE]
9.

Randomised comparison of CHOEP versus alternating hCHOP/IVEP for high-grade non-Hodgkin's lymphomas: treatment results and prognostic factor analysis in a multi-centre trial.

Köppler H, Pflüger KH, Eschenbach I, Pfab R, Birkmann J, Zeller W, Holle R, Steinhauer UE, Gropp C, Oehl S, et al.

Ann Oncol. 1994 Jan;5(1):49-55.

PMID:
8172793
[PubMed - indexed for MEDLINE]
10.

Community-based trial of R-CHOP and maintenance rituximab for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients.

Case DC Jr, Desch CE, Kalman LA, Vongkovit P, Mena RR, Fridman M, Allen B.

Clin Lymphoma Myeloma. 2007 Mar;7(5):354-60.

PMID:
17562245
[PubMed - indexed for MEDLINE]
11.

Fourteen-day CHOP supported with granulocyte colony-stimulating factor in patients with aggressive non-Hodgkin's lymphoma: results of a phase II study.

Gregory SA, Case DC Jr, Bosserman L, Litwak DL, Berry WR, Kalman LA, Belt RJ, Saven A.

Clin Lymphoma. 2003 Sep;4(2):93-8.

PMID:
14556680
[PubMed - indexed for MEDLINE]
12.

Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON).

Verdonck LF, Notenboom A, de Jong DD, MacKenzie MA, Verhoef GE, Kramer MH, Ossenkoppele GJ, Doorduijn JK, Sonneveld P, van Imhoff GW.

Blood. 2007 Apr 1;109(7):2759-66.

PMID:
17132720
[PubMed - indexed for MEDLINE]
Free Article
13.

Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).

Wunderlich A, Kloess M, Reiser M, Rudolph C, Truemper L, Bittner S, Schmalenberg H, Schmits R, Pfreundschuh M, Loeffler M; German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).

Ann Oncol. 2003 Jun;14(6):881-93.

PMID:
12796026
[PubMed - indexed for MEDLINE]
Free Article
14.

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.

Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, Pocock C, Ardeshna KM, Radford JA, McMillan A, Davies J, Turner D, Kruger A, Johnson P, Gambell J, Linch D.

Lancet. 2013 May 25;381(9880):1817-26. doi: 10.1016/S0140-6736(13)60313-X. Epub 2013 Apr 22.

PMID:
23615461
[PubMed - indexed for MEDLINE]
Free Article
15.

Phase II study of cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) therapy for newly diagnosed patients with low- and low-intermediate risk, aggressive non-Hodgkin's lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG9508.

Kagami Y, Itoh K, Tobinai K, Fukuda H, Mukai K, Chou T, Mikuni C, Kinoshita T, Fukushima N, Kiyama Y, Suzuki T, Sasaki T, Watanabe Y, Tsukasaki K, Hotta T, Shimoyama M, Ogura M; Lymphoma Study Group of the Japan Clinical Oncology Group.

Int J Hematol. 2012 Jul;96(1):74-83. doi: 10.1007/s12185-012-1101-2. Epub 2012 Jun 3.

PMID:
22661011
[PubMed - indexed for MEDLINE]
16.

High dose CHOP: a phase II study of initial treatment in aggressive non-Hodgkin lymphoma. Cancer and Leukemia Group B 9351.

Peterson BA, Johnson J, Shipp MA, Barcos M, Gockerman JP, Canellos GP; Cancer and Leukemia Group B 9351.

Leuk Lymphoma. 2007 May;48(5):870-80.

PMID:
17487729
[PubMed - indexed for MEDLINE]
17.

Long-term outcome of mesna, ifosfamide, mitoxantrone, etoposide (MINE) regimen as a consolidation in patients with aggressive non-Hodgkin lymphoma responding to CHOP.

Dincol D, Buyukcelik A, Dogan M, Akbulut H, Samur M, Demirkazik A, Senler FC, Onur H, Icli F.

Med Oncol. 2010 Sep;27(3):942-5. doi: 10.1007/s12032-009-9313-x. Epub 2009 Sep 29.

PMID:
19787462
[PubMed - indexed for MEDLINE]
18.

CHOP versus CHOP plus ESHAP and high-dose therapy with autologous peripheral blood progenitor cell transplantation for high-intermediate-risk and high-risk aggressive non-Hodgkin's lymphoma.

Intragumtornchai T, Prayoonwiwat W, Numbenjapon T, Assawametha N, O'Charoen R, Swasdikul D.

Clin Lymphoma. 2000 Dec;1(3):219-25.

PMID:
11707834
[PubMed - indexed for MEDLINE]
19.

A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas.

Sinha R, Kaufman JL, Khoury HJ Jr, King N, Shenoy PJ, Lewis C, Bumpers K, Hutchison-Rzepka A, Tighiouart M, Heffner LT, Lechowicz MJ, Lonial S, Flowers CR.

Cancer. 2012 Jul 15;118(14):3538-48. doi: 10.1002/cncr.26660. Epub 2012 Jan 3.

PMID:
22535574
[PubMed - indexed for MEDLINE]
Free Article
20.

A randomized trial comparing intensified CNOP vs. CHOP in patients with aggressive non-Hodgkin's lymphoma.

Pangalis GA, Vassilakopoulos TP, Michalis E, Roussou P, Vrakidou E, Repousis P, Angelopoulou MK, Siakantaris MP, Korantzis J, Symeonidis A, Grigorakis V, Stefanoudakis E, Stamatellou M, Bourantas KL, Kalmantis T, Christopoulos G, Kokkinis G, Mihalakeas I, Papayiannis A; Hellenic Cooperative Lymphoma Group.

Leuk Lymphoma. 2003 Apr;44(4):635-44.

PMID:
12769340
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk